Amgen reports positive results for Prolia
Thousand Oaks-based biotech giant Amgen announced positive results from patients receiving Prolia to treat inflammation Aug. 29. In the study, Prolia, normally used to treat osteoporosis, hypercalcemia and bone cancer, was used to treat inflammation. The two-year study enrolled 795 patients to evaluate the safety of two 60 milligram doses of Prolia given under the Read More →
Read More →Santa Barbara clinic tackles opioid abuse epidemic
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →Amgen alumni start their own biotech companies
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →SaniSure relocating from Oxnard to Camarillo
Medical device manufacturer SaniSure leased 32,000 square feet of industrial and office space at 1230 Calle Suerte in Camarillo. SaniSure is relocating its Oxnard operations to the NEFF Headwear property in Camarillo, CBRE said. “This building is a perfect fit for a company like SaniSure,” CBRE’s Jim Meaney said in a news release. “Ventura County Read More →
Read More →Sientra finds new factory to make breast implants
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →Abbvie sues Amgen to block sales of Humira biosimilar
Thousand Oaks-based biotech giant Amgen faces a lawsuit seeking to block it from selling a biosimilar of AbbVie’s popular Humira. The rheumatoid arthritis medicine is Abbvie’s best seller. Sales were up 17 percent in the second quarter to $4.15 billion and accounted for 61 percent of AbbVie’s 2015 revenue. Abbvie claims Amgen’s proposed copy would Read More →
Read More →CVS Health will not cover Amgen’s Neupogen in favor of Novartis biosimilar
CVS Health will no longer cover Thousand Oaks-based Amgen’s Neupogen on its standard drug plan in 2017, favoring the biosimilar Zarxio from Novartis. CVS, which is the second largest benefits manager behind Express Scripts and also owns the largest chain of drug stores in the U.S., said Aug. 2 it will choose biosimilar drugs over Read More →
Read More →
Sponsored content:
2015-2016 Giving Guide
